Paclibenz 260 Injection
Marketer
Admac Pharma Ltd
Salt Composition
Paclitaxel (6mg/ml)
Overview Paclibenz 260 Injection
Oncaspar 260 Injection is a chemotherapeutic agent indicated for treating breast, pancreatic, and non-small cell lung cancers. Administered intravenously by a healthcare professional, the dosage and frequency are determined by your physician based on your condition and may be adjusted. Strict adherence to the prescribed regimen is crucial, as incorrect usage or overdose can lead to severe adverse reactions. Therapeutic effects may take weeks or months to manifest; discontinuation should only occur under medical supervision. Common side effects include nausea, emesis, and fatigue. Serious side effects such as edema (hands/lips), alopecia, and weight increase are possible. Concomitant medication may be prescribed to mitigate these effects. Report any unusual bruising, bleeding, pharyngitis, oral ulcers, or pyrexia immediately. This medication can suppress blood cell counts (red and white), raising infection risk. Regular blood tests monitoring blood cell levels and liver function are mandatory. Prior to commencing treatment, disclose any pre-existing cardiac, hepatic, or renal conditions, and all other medications, particularly anti-infectives, as drug interactions are possible. This medication is contraindicated in pregnancy and lactation; reliable contraception for both partners is essential throughout treatment.
Uses of Paclibenz 260 Injection
Cancers of the breast, lung (non-small cell type), and pancreas
Major Benefits of Paclibenz 260 Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
Common Side effects of Paclibenz 260 Injection:
- Nausea
- Vomiting
- Weakness
- Low blood platelets
- Rash
- Upper respiratory tract infection
- Urinary tract infection
- Bleeding
- Anemia (low number of red blood cells)
- Flushing (sense of warmth in the face, ears, neck and trunk)
- Hair loss
- Decreased blood pressure
- Peripheral neuropathy (tingling and numbness of feet and hand)
- Diarrhea
- Decreased white blood cell count (neutrophils)
How to use Paclibenz 260 Injection:
Administering this medication will be done by your physician or registered nurse; self-medication is strictly prohibited.
How Paclibenz 260 Injection works:
Paclibenz 260 Injection is a cancer treatment that disrupts the microtubules crucial for cancer cell division and proliferation. This action inhibits cancer cell growth, ultimately leading to their demise.
SAFETY ADVICE
AlcoholUNSAFE
Combining Paclibenz 260 Injection and alcohol is unsafe.
PregnancyCONSULT YOUR DOCTOR
Administering Paclibenz 260 Injection during pregnancy poses a confirmed risk to fetal development and is therefore contraindicated. In exceptional, life-threatening circumstances, a physician might consider its use only when the potential benefits demonstrably outweigh the hazards. Physician consultation is essential.
Breast feedingUNSAFE
Administering Paclibenz 260 Injection while breastfeeding is contraindicated. Evidence indicates potential infant toxicity from this medication.
DrivingUNSAFE
Driving ability may be impaired by Paclibenz 260 Injection side effects. While there's no inherent prohibition on driving between treatment cycles, the injection's alcohol content suggests caution regarding operating a vehicle.
KidneySAFE IF PRESCRIBED
Paclibenz 260 Injection poses no safety concerns for individuals with kidney impairment; no dosage modification is necessary. Nevertheless, consultation with a physician is advised if you have pre-existing kidney conditions.
LiverCAUTION
Administering Paclibenz 260 Injection to individuals with hepatic impairment requires careful consideration. Dosage modification of Paclibenz 260 Injection might be necessary. Physician consultation is advised. Paclibenz 260 Injection is contraindicated in patients exhibiting severe liver dysfunction.
What if you forget to take Paclibenz 260 Injection :
NA
Facts to Know About Paclibenz 260 Injection
| Label | Value |
|---|---|
| Type of Compound | Taxane-based medications |
| Addictive | None. |
| Medication Classification | Cancer therapies |
| Mechanism of Action | Microtubule-targeting drugs: Taxane class |
3,018 People bought this recently